Skip to content
InMed-logo-01
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
Menu
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
TSX_Logo
NASDAQ_Logo

In the Media

  • May 11, 2020

InMed’s therapeutic development of cannabinol and update on programs – Executive Interview with CEO Eric A. Adams

In this video, InMed Pharmaceuticals’ CEO Eric A. Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat serious diseases with high unmet needs. InMed is the first company to advance CBN into clinical trials for therapeutic development. Mr. Adams also provides an update on the company’s programs in epidermolysis bullosa (EB) and glaucoma and its biosynthesis platform.

Full Article
Source: Edison TV

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Latest Articles

InMed’s CEO Eric A. Adams presents at Edison Open House: Global Healthcare 2021

InMed Pharmaceuticals CEO, Eric A. Adams, is interviewed by Science Journalist and Broadcaster Vivienne Parry Obe at the Edison Open House: Global Healthcare Conference 2021.

Read More
February 18, 2021

Cannabinol 101: The Science of Cannabinol (CBN)

Cannabinol, or CBN for short, is one of the more than 100 rare cannabinoids found in the Cannabis plant. CBN is found in aged Cannabis

Read More
June 8, 2020

InMed’s cannabinol (CBN) formulation for glaucoma – Executive Interview with CEO Eric A. Adams

In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to

Read More
May 27, 2020
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4
Science
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • IntegraSyn™ Cannabinoid Manufacturing
  • InMed’s Research of Rare Cannabinoids

Investor

  • News Releases
  • Latest Presentation
  • Letter to Shareholders
  • SEDAR® Filings
  • Financial Reports
  • Sign up for Investor Alerts

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Corporate Governance
  • Partners and Collaborators
  • Events Calendar
  • Careers

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2021 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On: